{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T14:00:09Z","timestamp":1788357609022,"version":"build-2803163510"},"reference-count":63,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T00:00:00Z","timestamp":1747180800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Oncology"],"abstract":"<jats:p>Enfortumab vedotin (EV) in combination with pembrolizumab (P) has led to a new paradigm for the treatment of metastatic urothelial carcinoma (mUC). Since the presentation of the results of the EV-302 trial at the European Society of Medical Oncology 2023 annual meeting, the entire treatment landscape for mUC has been upended. At the 2024 Albert Symposium, we reviewed ongoing research investigating predictive biomarkers for EV response and resistance as well as clinical trials exploring the potential role for EV in different clinical disease states including non-muscle invasive and muscle-invasive disease.<\/jats:p>","DOI":"10.3390\/curroncol32050278","type":"journal-article","created":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T08:44:58Z","timestamp":1747212298000},"page":"278","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Mechanistic Insights and Future Directions for Enfortumab Vedotin in Urothelial Carcinoma: Highlights from the 10th Annual Leo &amp; Anne Albert Institute for Bladder Cancer Care and Research Symposium"],"prefix":"10.3390","volume":"32","author":[{"given":"Catherine C.","family":"Fahey","sequence":"first","affiliation":[{"name":"Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC 27599, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean","family":"Clark-Garvey","sequence":"additional","affiliation":[{"name":"Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC 27599, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sima","family":"Porten","sequence":"additional","affiliation":[{"name":"Department of Urology, University of California, San Francisco, CA 94143, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashish M.","family":"Kamat","sequence":"additional","affiliation":[{"name":"Department of Urology, MD Anderson Cancer Center, Houston, TX 77030, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas W.","family":"Flaig","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Colorado, Aurora, CO 80045, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John A.","family":"Taylor","sequence":"additional","affiliation":[{"name":"Department of Urology, University of Kansas, Kansas City, KS 66160, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7922-2156","authenticated-orcid":false,"given":"William Y.","family":"Kim","sequence":"additional","affiliation":[{"name":"Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC 27599, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8965-8129","authenticated-orcid":false,"given":"Matthew I.","family":"Milowsky","sequence":"additional","affiliation":[{"name":"Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC 27599, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,5,14]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1056\/NEJMoa2035807","article-title":"Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma","volume":"384","author":"Powles","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"4107","DOI":"10.1200\/JCO.2023.41.6_suppl.439","article-title":"Enfortumab Vedotin with or Without Pembrolizumab in Cisplatin-Ineligible Patients with Previously Untreated Locally Advanced or Metastatic Urothelial Cancer","volume":"41","author":"Milowsky","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1056\/NEJMoa2312117","article-title":"Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer","volume":"390","author":"Powles","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1200\/JCO.2025.43.5_suppl.664","article-title":"EV-302: Updated Analysis from the Phase 3 Global Study of Enfortumab Vedotin in Combination with Pembrolizumab (EV+P) vs Chemotherapy (Chemo) in Previously Untreated Locally Advanced or Metastatic Urothelial Carcinoma (La\/mUC)","volume":"43","author":"Powles","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"ref_5","unstructured":"(2024, November 06). EAU Guidelines\u2014Uroweb. Available online: https:\/\/uroweb.org\/guidelines\/muscle-invasive-and-metastatic-bladder-cancer."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"216","DOI":"10.6004\/jnccn.2024.0024","article-title":"NCCN Guidelines\u00ae Insights: Bladder Cancer, Version 3.2024: Featured Updates to the NCCN Guidelines","volume":"22","author":"Flaig","year":"2024","journal-title":"J. Natl. Compr. Canc. Netw."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.annonc.2024.03.001","article-title":"ESMO Clinical Practice Guideline Interim Update on First-Line Therapy in Advanced Urothelial Carcinoma","volume":"35","author":"Powles","year":"2024","journal-title":"Ann. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1158\/1535-7163.MCT-21-0846","article-title":"The Anti-Nectin 4: A Promising Tumor Cells Target. A Systematic Review","volume":"21","author":"Bouleftour","year":"2022","journal-title":"Mol. Cancer Ther."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"3003","DOI":"10.1158\/0008-5472.CAN-15-1313","article-title":"Enfortumab Vedotin Antibody\u2013Drug Conjugate Targeting Nectin-4 Is a Highly Potent Therapeutic Agent in Multiple Preclinical Cancer Models","volume":"76","author":"Satpayev","year":"2016","journal-title":"Cancer Res."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Olson, D., Younan, P., Liu, B., Blahnik-Fagan, G., Gosink, J., Snead, K., Tenn, E., Hensley, K., Sahetya, D., and Nesterova, A. (2022). 1187 Enfortumab Vedotin Induces Immunogenic Cell Death, Elicits Antitumor Immune Memory, and Shows Enhanced Preclinical Activity in Combination with Immune Checkpoint Inhibitors. J. Immunother. Cancer, 10.","DOI":"10.1136\/jitc-2022-SITC2022.1187"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"e000337","DOI":"10.1136\/jitc-2019-000337","article-title":"Consensus Guidelines for the Definition, Detection and Interpretation of Immunogenic Cell Death","volume":"8","author":"Galluzzi","year":"2020","journal-title":"J. Immunother. Cancer"},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Garg, A.D., Galluzzi, L., Apetoh, L., Baert, T., Birge, R.B., Bravo-San Pedro, J.M., Breckpot, K., Brough, D., Chaurio, R., and Cirone, M. (2015). Molecular and Translational Classifications of DAMPs in Immunogenic Cell Death. Front. Immunol., 6.","DOI":"10.3389\/fimmu.2015.00588"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"115534","DOI":"10.1016\/j.taap.2021.115534","article-title":"Microtubule and Tubulin Binding and Regulation of Microtubule Dynamics by the Antibody Drug Conjugate (ADC) Payload, Monomethyl Auristatin E (MMAE): Mechanistic Insights into MMAE ADC Peripheral Neuropathy","volume":"421","author":"Best","year":"2021","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"ref_14","first-page":"A654","article-title":"618 Vedotin ADCs Induce ER Stress and Elicit Hallmarks of ICD across Multiple Cancer Indications","volume":"8","author":"Klussman","year":"2020","journal-title":"J. Immunother. Cancer"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"102415","DOI":"10.1016\/j.eclinm.2023.102415","article-title":"Disitamab Vedotin (RC48) plus Toripalimab for HER2-Expressing Advanced Gastric or Gastroesophageal Junction and Other Solid Tumours: A Multicentre, Open Label, Dose Escalation and Expansion Phase 1 Trial","volume":"68","author":"Wang","year":"2024","journal-title":"eClinicalMedicine"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1182\/blood-2022-156553","article-title":"Brentuximab Vedotin, Nivolumab, Doxorubicin, and Dacarbazine (AN+AD) for Advanced Stage Classic Hodgkin Lymphoma: Updated Efficacy and Safety Results from the Single-Arm Phase 2 Study (SGN35-027 Part B)","volume":"140","author":"Lee","year":"2022","journal-title":"Blood"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"5536","DOI":"10.1200\/JCO.23.00720","article-title":"Tisotumab Vedotin in Combination With Carboplatin, Pembrolizumab, or Bevacizumab in Recurrent or Metastatic Cervical Cancer: Results From the innovaTV 205\/GOG-3024\/ENGOT-Cx8 Study","volume":"41","author":"Vergote","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.annonc.2024.12.002","article-title":"Disitamab Vedotin plus Toripalimab in Patients with Locally Advanced or Metastatic Urothelial Carcinoma (RC48-C014): A Phase 1b\/2 Dose-Escalation and Dose-Expansion Study","volume":"36","author":"Zhou","year":"2024","journal-title":"Ann. Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1200\/JCO.2022.40.6_suppl.438","article-title":"Primary Analysis from DS8201-A-U105: A Phase 1b, Two-Part, Open-Label Study of Trastuzumab Deruxtecan (T-DXd) with Nivolumab (Nivo) in Patients (Pts) with HER2-Expressing Urothelial Carcinoma (UC)","volume":"40","author":"Galsky","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.euros.2023.01.002","article-title":"Enfortumab Vedotin-Related Cutaneous Toxicity and Radiographic Response in Patients with Urothelial Cancer: A Single-Center Experience and Review of the Literature","volume":"49","author":"Vlachou","year":"2023","journal-title":"Eur. Urol. Open Sci."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Vlachou, E., Johnson, B.A., McConkey, D., Jing, Y., Matoso, A., Hahn, N.M., and Hoffman-Censits, J. (2024). Enfortumab Vedotin-Related Cutaneous Toxicity Correlates with Overall Survival in Patients with Urothelial Cancer: A Retrospective Experience. Front. Oncol., 14.","DOI":"10.3389\/fonc.2024.1377842"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"e223","DOI":"10.1093\/oncolo\/oyac001","article-title":"Management of Dermatologic Events Associated With the Nectin-4-Directed Antibody-Drug Conjugate Enfortumab Vedotin","volume":"27","author":"Lacouture","year":"2022","journal-title":"Oncologist"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"5123","DOI":"10.1158\/1078-0432.CCR-20-4175","article-title":"Heterogeneity in NECTIN4 Expression Across Molecular Subtypes of Urothelial Cancer Mediates Sensitivity to Enfortumab Vedotin","volume":"27","author":"Chu","year":"2021","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1200\/JCO.19.02044","article-title":"EV-101: A Phase I Study of Single-Agent Enfortumab Vedotin in Patients With Nectin-4\u2013Positive Solid Tumors, Including Metastatic Urothelial Carcinoma","volume":"38","author":"Rosenberg","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1158\/1078-0432.CCR-22-1764","article-title":"Membranous NECTIN-4 Expression Frequently Decreases during Metastatic Spread of Urothelial Carcinoma and Is Associated with Enfortumab Vedotin Resistance","volume":"29","author":"Ralser","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"2446","DOI":"10.1200\/JCO.23.01983","article-title":"NECTIN4 Amplification Is Frequent in Solid Tumors and Predicts Enfortumab Vedotin Response in Metastatic Urothelial Cancer","volume":"42","author":"Tran","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"4595","DOI":"10.1200\/JCO.2023.41.16_suppl.4595","article-title":"Study EV-103: Neoadjuvant Treatment with Enfortumab Vedotin Monotherapy in Cisplatin-Ineligible Patients (Pts) with Muscle Invasive Bladder Cancer (MIBC): Updated Results for Cohort H","volume":"41","author":"Flaig","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"S1203","DOI":"10.1016\/j.annonc.2023.09.1014","article-title":"2365MO Study EV-103 Cohort L: Perioperative Treatment w\/Enfortumab Vedotin (EV) Monotherapy in Cisplatin (Cis)-Ineligible Patients (Pts) w\/Muscle Invasive Bladder Cancer (MIBC)","volume":"34","author":"Sridhar","year":"2023","journal-title":"Ann. Oncol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"TPS588","DOI":"10.1200\/JCO.2023.41.6_suppl.TPS588","article-title":"Perioperative Enfortumab Vedotin (EV) plus Pembrolizumab (Pembro) versus Chemotherapy in Cisplatin-Eligible Patients (Pts) with Muscle-Invasive Bladder Cancer (MIBC): Phase 3 KEYNOTE-B15\/EV-304","volume":"41","author":"Hoimes","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1056\/NEJMoa2408154","article-title":"Perioperative Durvalumab with Neoadjuvant Chemotherapy in Operable Bladder Cancer","volume":"391","author":"Powles","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.1056\/NEJMoa2034442","article-title":"Adjuvant Nivolumab versus Placebo in Muscle-Invasive Urothelial Carcinoma","volume":"384","author":"Bajorin","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_32","unstructured":"(2025, May 02). A Phase 3, Randomized, Open-Label Study to Evaluate Perioperative Enfortumab Vedotin Plus Pembrolizumab (MK-3475) Versus Neoadjuvant Gemcitabine and Cisplatin in Cisplatin-Eligible Participants with Muscle-Invasive Bladder Cancer (MK-3475-B15\/KEYNOTE-B15\/EV-304), Available online: https:\/\/clinicaltrials.gov\/study\/NCT04700124."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"TPS507","DOI":"10.1200\/JCO.2021.39.6_suppl.TPS507","article-title":"KEYNOTE-905\/EV-303: Perioperative Pembrolizumab or Pembrolizumab plus Enfortumab Vedotin (EV) and Cystectomy Compared to Cystectomy Alone in Cisplatin-Ineligible Patients with Muscle-Invasive Bladder Cancer (MIBC)","volume":"39","author":"Galsky","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_34","unstructured":"(2025, May 02). A Randomized Phase 3 Study Evaluating Cystectomy With Perioperative Pembrolizumab and Cystectomy With Perioperative Enfortumab Vedotin and Pembrolizumab Versus Cystectomy Alone in Participants Who Are Cisplatin-Ineligible or Decline Cisplatin with Muscle-Invasive Bladder Cancer (KEYNOTE-905\/EV-303), Available online: https:\/\/clinicaltrials.gov\/study\/NCT03924895."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"TPS579","DOI":"10.1200\/JCO.2022.40.6_suppl.TPS579","article-title":"A Phase 3, Randomized, Open-Label, Multicenter, Global Study of the Efficacy and Safety of Durvalumab (D) + Tremelimumab (T) + Enfortumab Vedotin (EV) or D + EV for Neoadjuvant Treatment in Cisplatin-Ineligible Muscle-Invasive Bladder Cancer (MIBC) (VOLGA)","volume":"40","author":"Powles","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_36","unstructured":"(2025, May 02). A Phase III Randomized, Open-Label, Multicenter Study to Determine the Efficacy and Safety of Durvalumab in Combination With Tremelimumab and Enfortumab Vedotin or Durvalumab in Combination With Enfortumab Vedotin for Perioperative Treatment in Patients Ineligible for Cisplatin or Who Refuse Cisplatin Undergoing Radical Cystectomy for Muscle Invasive Bladder Cancer (VOLGA), Available online: https:\/\/clinicaltrials.gov\/study\/NCT04960709."},{"key":"ref_37","unstructured":"(2025, May 02). Enfortumab Vedotin in Combination with Pembrolizumab for Locally Advanced and\/or Node Positive Urothelial Carcinoma Prior to Surgery (EV-ECLIPSE), Available online: https:\/\/clinicaltrials.gov\/study\/NCT05239624."},{"key":"ref_38","unstructured":"(2025, May 02). A Phase 1\/2 Study of V940 Plus Pembrolizumab with or Without Enfortumab Vedotin in Muscle-Invasive Urothelial Carcinoma (MIUC) (INTerpath-005), Available online: https:\/\/clinicaltrials.gov\/study\/NCT06305767."},{"key":"ref_39","unstructured":"(2024, November 15). Phase Ib\/II Study of Enfortumab Vedotin and Pembrolizumab Combined with Radiotherapy as a Bladder-Sparing Trimodality Therapy in Muscle Invasive Bladder Cancer, Available online: https:\/\/clinicaltrials.gov\/study\/NCT06470282."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"TPS582","DOI":"10.1200\/JCO.2023.41.6_suppl.TPS582","article-title":"Study EV-104: Phase 1 Study of Intravesical Enfortumab Vedotin for Treatment of Patients with Non-Muscle Invasive Bladder Cancer (NMIBC)\u2014Trial in Progress","volume":"41","author":"Kamat","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/S1470-2045(21)00147-9","article-title":"Pembrolizumab Monotherapy for the Treatment of High-Risk Non-Muscle-Invasive Bladder Cancer Unresponsive to BCG (KEYNOTE-057): An Open-Label, Single-Arm, Multicentre, Phase 2 Study","volume":"22","author":"Balar","year":"2021","journal-title":"Lancet Oncol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1097\/JU.0000000000004020","article-title":"Efficacy of Intravesical Nadofaragene Firadenovec for Patients With Bacillus Calmette-Gu\u00e9rin-Unresponsive Nonmuscle-Invasive Bladder Cancer: 5-Year Follow-Up From a Phase 3 Trial","volume":"212","author":"Narayan","year":"2024","journal-title":"J. Urol."},{"key":"ref_43","first-page":"EVIDoa2200167","article-title":"IL-15 Superagonist NAI in BCG-Unresponsive Non\u2013Muscle-Invasive Bladder Cancer","volume":"2","author":"Chamie","year":"2022","journal-title":"NEJM Evid."},{"key":"ref_44","unstructured":"(2025, May 04). FDA Approves Pembrolizumab for BCG-Unresponsive, High-Risk Non-Muscle Invasive Bladder Cancer, Available online: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-pembrolizumab-bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer."},{"key":"ref_45","unstructured":"(2025, May 04). FDA Approves First Adenoviral Vector-Based Gene Therapy for High-Risk Bacillus Calmette-Gu\u00e9rin Unresponsive Non-Muscle Invasive Bladder Cancer, Available online: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-first-adenoviral-vector-based-gene-therapy-high-risk-bacillus-calmette-guerin."},{"key":"ref_46","unstructured":"(2025, May 04). FDA Approves Nogapendekin Alfa Inbakicept-Pmln for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer, Available online: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-nogapendekin-alfa-inbakicept-pmln-bcg-unresponsive-non-muscle-invasive-bladder-cancer."},{"key":"ref_47","unstructured":"(2025, March 27). A Phase II, Open-Label, Single-Arm, Multi-Center Study of Neoadjuvant Enfortumab Vedotin and Pembrolizumab in Cisplatin-Eligible Upper Tract Urothelial Cancer (NEPTUNE), Available online: https:\/\/clinicaltrials.gov\/study\/NCT06356155."},{"key":"ref_48","unstructured":"(2025, March 27). Neoadjuvant Enfortumab Vedotin in High-Grade Urothelial Carcinoma of the Upper Urinary Tract (Including Ureter and Renal Pelvis), Available online: https:\/\/clinicaltrials.gov\/study\/NCT05868265."},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Li, K., Zhou, Y., Zang, M., Jin, X., and Li, X. (2024). Therapeutic Prospects of Nectin-4 in Cancer: Applications and Value. Front. Oncol., 14.","DOI":"10.3389\/fonc.2024.1354543"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"122910","DOI":"10.1016\/j.lfs.2024.122910","article-title":"Nectin-4-Directed Antibody-Drug Conjugates (ADCs): Spotlight on Preclinical and Clinical Evidence","volume":"352","author":"Khosravanian","year":"2024","journal-title":"Life Sci."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1158\/1535-7163.MCT-22-0743","article-title":"Preclinical Evaluation of 9MW2821, a Site-Specific Monomethyl Auristatin E\u2013Based Antibody\u2013Drug Conjugate for Treatment of Nectin-4\u2013Expressing Cancers","volume":"22","author":"Zhou","year":"2023","journal-title":"Mol. Cancer Ther."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1200\/JCO.2024.42.4_suppl.622","article-title":"Phase 1 Dose Escalation of SYS6002 (CRB-701), a next-Generation Nectin-4 Targeting Antibody Drug Conjugate (ADC)","volume":"42","author":"Ye","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"CT084","DOI":"10.1158\/1538-7445.AM2024-CT084","article-title":"Abstract CT084: A Phase 1 Study of LY4101174 (ETx-22), an Antibody-Drug Conjugate Targeting Nectin-4, in Patients with Advanced or Metastatic Urothelial Cancer and Other Solid Tumors (Trial in Progress)","volume":"84","author":"Rosenberg","year":"2024","journal-title":"Cancer Res."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"e16567","DOI":"10.1200\/JCO.2024.42.16_suppl.e16567","article-title":"A Phase 1 Study of BAT8007, an Anti-Nectin-4 Monoclonal Antibody-Exatecan Conjugate, in Patients with Advanced Solid Tumors","volume":"42","author":"Jiang","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.1158\/1538-7445.AM2024-1902","article-title":"Abstract 1902: ADRX-0706 Nectin-4 Antibody-Drug Conjugate PK\/PD Characterization Elucidates Its Widened Therapeutic Window","volume":"84","author":"Shahmoradgoli","year":"2024","journal-title":"Cancer Res."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.1158\/1538-7445.AM2024-1872","article-title":"Abstract 1872: A next Generation Treatment for Nectin-4 Positive Cancers\u2014Preclinical Characterization of LY4052031, an Anti-Nectin-4 Antibody, Conjugated to a Novel Camptothecin Payload","volume":"84","author":"Sagar","year":"2024","journal-title":"Cancer Res."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1200\/JCO.2025.43.5_suppl.657","article-title":"Nectin-4 Targeted ADC, SHR-A2102, in Patients with Advanced or Metastatic Urothelial Carcinoma: A Phase 1 Study","volume":"43","author":"Tang","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"4560","DOI":"10.1158\/1538-7445.AM2020-4560","article-title":"Abstract 4560: Conditionally Active Biologics (CAB): A Novel Class of Molecules Targeting Solid Tumors","volume":"80","author":"Wang","year":"2020","journal-title":"Cancer Res."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1158\/1538-7445.AM2023-1541","article-title":"Abstract 1541: NextGen Conditionally Active Biologic (CAB) Anti-Nectin-4-ADC with Improved Stability and Safety","volume":"83","author":"Frey","year":"2023","journal-title":"Cancer Res."},{"key":"ref_60","unstructured":"(2024, December 13). BioAtla Announces FDA Clearance of Investigational New Drug Application for BA3361, a CAB-Nectin-4 Antibody Drug Conjugate for the Treatment of Multiple Tumors. Available online: https:\/\/www.globenewswire.com\/news-release\/2024\/05\/06\/2875781\/0\/en\/BioAtla-Announces-FDA-Clearance-of-Investigational-New-Drug-Application-for-BA3361-a-CAB-Nectin-4-Antibody-Drug-Conjugate-for-the-Treatment-of-Multiple-Tumors.html."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1158\/1535-7163.MCT-21-0875","article-title":"BT8009; A Nectin-4 Targeting Bicycle Toxin Conjugate for Treatment of Solid Tumors","volume":"21","author":"Rigby","year":"2022","journal-title":"Mol. Cancer Ther."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"e002883","DOI":"10.1136\/jitc-2021-002883","article-title":"BT7480, a Novel Fully Synthetic Bicycle Tumor-Targeted Immune Cell AgonistTM (Bicycle TICATM) Induces Tumor Localized CD137 Agonism","volume":"9","author":"Hurov","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"116725","DOI":"10.1016\/j.ejmech.2024.116725","article-title":"PROTAC Technology: From Drug Development to Probe Technology for Target Deconvolution","volume":"276","author":"Yan","year":"2024","journal-title":"Eur. J. Med. Chem."}],"container-title":["Current Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1718-7729\/32\/5\/278\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T17:32:27Z","timestamp":1760031147000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1718-7729\/32\/5\/278"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,14]]},"references-count":63,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2025,5]]}},"alternative-id":["curroncol32050278"],"URL":"https:\/\/doi.org\/10.3390\/curroncol32050278","relation":{},"ISSN":["1718-7729"],"issn-type":[{"value":"1718-7729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,14]]}}}